International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting

Alison H Kohn; Afsaneh Alavi; April W Armstrong; Folawiyo Babalola; Amit Garg; Alice B Gottlieb; Lesley Grilli; Gregor Borut Ernst Jemec; John Latella; Kendall Marcus; Joseph F Merola; Alex G Ortega-Loayza; Daniel M Siegel; Vibeke Strand; Jerry K L Tan; Lourdes M Perez-Chada

doi:10.1159/000518966

International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting

Dermatology. 2022;238(3):430-437. doi: 10.1159/000518966. Epub 2021 Sep 17.

Authors

Alison H Kohn¹, Afsaneh Alavi^{2

3}, April W Armstrong⁴, Folawiyo Babalola⁵, Amit Garg⁶, Alice B Gottlieb⁷, Lesley Grilli⁸, Gregor Borut Ernst Jemec⁹, John Latella¹⁰, Kendall Marcus¹¹, Joseph F Merola¹², Alex G Ortega-Loayza¹³, Daniel M Siegel¹⁴, Vibeke Strand¹⁵, Jerry K L Tan¹⁶, Lourdes M Perez-Chada¹⁷

Affiliations

¹ Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida, USA.
² Division of Dermatology, University of Toronto, Toronto, Ontario, Canada.
³ Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA.
⁴ Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA, armstrongpublication@gmail.com.
⁵ Joe R. & Teresa Lozano Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
⁶ Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York, USA.
⁷ Department of Dermatology, Icahn School of Medicine at Mt Sinai, New York, New York, USA.
⁸ Patient Research Partner, International Dermatology Outcome Measures (IDEOM), Cohasset, Massachusetts, USA.
⁹ Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.
¹⁰ Patient Research Partner, International Dermatology Outcome Measures (IDEOM), Windsor, Connecticut, USA.
¹¹ Division of Dermatology and Dental Products, Office of New Drugs, US Food and Drug Administration, Silver Spring, Maryland, USA.
¹² Department of Dermatology and Medicine, Division of Rheumatology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.
¹³ Department of Dermatology, Oregon Health and Science University, Portland, Oregon, USA.
¹⁴ Department of Dermatology, SUNY Downstate Medical Center, Brooklyn, New York, USA.
¹⁵ Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA.
¹⁶ Faculty of Medicine, Western University, London, Ontario, Canada.
¹⁷ Department of Dermatology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Abstract

Background: The International Dermatology Outcome Measures (IDEOM) initiative is a non-profit organization that aims to develop evidence-based outcome measurements to evaluate the impact of treatments for patients with dermatological disease. IDEOM includes all key stakeholders in dermatology (patient, physician, industry, insurer, and government) during the process of developing such outcome measurements.

Summary: Here, we provide an update of IDEOM activities that were presented at the 2020 IDEOM Virtual Annual Meeting (October 23-24, 2020). During the meeting, multiple IDEOM workgroups (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) shared their progress to date, as well as future directions in developing and validating Patient-Reported Outcome Measures. Updates on demonstrating efficacy in clinicals trials by the US Food and Drug Administration are also summarized.

Key messages: In this report, we summarize the work presented by each IDEOM workgroup (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) at the 2020 IDEOM Virtual Annual Meeting.

Keywords: Acne; Actinic keratosis; Hidradenitis suppurativa; IDEOM; Patient-Reported Outcome Measures; Psoriasis; Psoriatic arthritis; Pyoderma gangrenosum.

The Author(s). Published by S. Karger AG, Basel.

Publication types

Review

MeSH terms

Acne Vulgaris*
Arthritis, Psoriatic* / diagnosis
Arthritis, Psoriatic* / drug therapy
Dermatology*
Hidradenitis Suppurativa*
Humans
Keratosis, Actinic*
Outcome Assessment, Health Care
Psoriasis* / therapy
Pyoderma Gangrenosum*